Ren-Ke Li (Li Renke)

Ren-Ke Li, known professionally in China as Li Renke, was a cardiac surgeon-scientist whose research helped lay the groundwork for using stem cells and engineered tissue to repair hearts damaged by disease and heart attacks. He spent most of his career in Canada, where he held a senior position in cardiac surgery research affiliated with the University of Toronto and its teaching hospitals, before becoming a frequently invited speaker and collaborator at cardiovascular science meetings in China. Colleagues in the field described him as one of the early pioneers who pushed cardiac cell therapy from a laboratory idea toward real clinical possibility.

Li's scientific contribution centred on a question that had frustrated heart specialists for decades: once heart muscle is scarred by a heart attack or weakened by chronic failure, can it be regrown or repaired rather than simply managed with drugs and devices. His laboratory work explored transplanting a patient's own cells, including muscle and stem cells, into damaged heart tissue, and he contributed to the broader field of cardiac tissue engineering that sought to build functional heart muscle patches in the laboratory. This research placed him among a small international group of surgeon-scientists credited with moving heart regeneration research out of theory and into early clinical trials over the 2000s and 2010s.

Beyond the laboratory, Li was known for training younger cardiac researchers and for his long involvement in both North American and Chinese scientific circles, giving him an unusually international profile for a specialist in such a technical field. He continued to travel, lecture and collaborate across borders well into his sixties, reflecting the global and still-advancing nature of cardiac regenerative medicine, a field that as of 2026 had produced promising experimental results but had not yet delivered a routine cure for heart failure.

Li Renke died on October 10, 2026, at the age of 65, while attending a scientific meeting in China, according to the first reports of his death. The exact city and venue of the meeting, and the circumstances in which he died, have not yet been widely detailed in public reporting. News of his death began circulating through cardiovascular research and Chinese medical science circles, with early accounts describing him as a pioneering heart stem cell expert whose loss was felt across the cardiac research community. As of this writing, the cause of death has not been made public, and further details about his death, his full biography and his survivors are expected to emerge in the coming days.

This page will be updated as verified information becomes available, including confirmation of his education, family, and the precise circumstances of his death, along with reactions from institutions and colleagues who worked alongside him.